10x Genomics (NASDAQ:TXG) Given New $18.00 Price Target at Stifel Nicolaus
Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
10x Genomics (TXG) Receives a Buy from Morgan Stanley
Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...
10x Genomics price target lowered to $15 from $18 at Barclays
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Hosted on MSN1d
Leerink Partners Downgrades 10x Genomics (TXG)
Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...
Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties
Genomics reported a Q4 EPS loss of $(0.40), missing estimates, while revenue declined 10% year over year. Analysts lowered price targets amid profitability concerns.
StockStory.org on MSN1d
Why 10x Genomics (TXG) Shares Are Falling Today
What Happened? Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company ...
10x Genomics sees robust growth across platforms in Q4 2023
CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with ...
FierceBiotech4d
DNA sequencing shares slide amid 'headwinds' from Trump's NIH funding cuts
After the National Institutes of Health (NIH) announced late Friday that it would be following a Trump administration ...